Clinical trials: Docetaxel, completed
Non-Small Cell Lung Cancer
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
The purpose of this study is to evaluate how tumors in patients with non-small cell lung cancer respond to treatment with VELCADE alone versus VELCADE given with docetaxel and also to see what effects (good and bad) it has on you…
- Trial name
- NCT00051974
- Testing
- VELCADE™ (bortezomib) for Injection (formerly PS-341)
- Where
- 20 sites in United States
- Volunteers
- 155 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Tumors, Neoplasms
Phase I Study of LB-100 With Docetaxel in Solid Tumors
The purpose of this study is to test the safety of an investigational drug called LB-100 for Injection for treatment of solid tumors, when given with or without docetaxel.
- Conditions
- Tumors, Neoplasms, Cancer
- Trial name
- NCT01837667
- Testing
- LB-100 for Injection, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 29 people
- Sponsor
- Lixte Biotechnology Holdings, Inc.
Lung Cancer
Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00030771
- Testing
- Chemotherapy, Radiotherapy, Surgery
- Where
- 25 sites in Germany, Serbia and 1 more
- Volunteers
- 232 people
- Sponsor
- Swiss Cancer Institute
Breast Cancer
S0215 Trastuzumab, Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as trastuzumab, can locate tumor cells and either kill them or deliver…
- Trial name
- NCT00041067
- Testing
- filgrastim, trastuzumab, docetaxel
- Where
- 145 sites in United States
- Volunteers
- 76 people
- Sponsor
- SWOG Cancer Research Network
Prostate Cancer
Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Following a radical prostatectomy and lymph node sampling, eligible patients will undergo post-operative radiation therapy, concurrent weekly docetaxel chemotherapy , and hormonal therapy (Casodex daily and Zoladex every 3 months…
- Trial name
- NCT00669162
- Testing
- Docetaxel, Radiation Therapy, Casodex and Zoladex (or Lupron)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Kansas Medical Center
Stomach Neoplasms, Neoplasms Metastasis
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Patients with inoperable, locally advanced or recurrent and/or HER2-positive metastatic gastric or gastro-esophageal junction cancer, with no prior treatment for metastatic disease are to be recruited in the study.
- Conditions
- Stomach Neoplasms, Neoplasms Metastasis, ERBB2 Gene Amplification
- Trial name
- NCT02004769
- Testing
- Trastuzumab, Docetaxel, Capecitabine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Sun Yat-sen University
Hormone Refractory Prostate Cancer
ABI-008 Trial in Patients With Hormone-refractory Prostate Cancer
To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of ABI-008 given every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given…
- Trial name
- NCT00477529
- Testing
- ABI-008
- Where
- 4 sites in United States
- Volunteers
- 102 people
- Sponsor
- Celgene
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Tumor
A Phase Ⅰa Clinical Study Exploring Efficacy of SIBP-03 When Treating the Patients With Advanced Malignant Solid Tumors.
The main purpose of To evaluate the safety, tolerability and pharmacokinetic characteristics of SIBP-03（Recombinant anti-HER3 humanized monoclonal antibody injection）. A secondary purpose Assess the immunogenicity of SIBP-03.
- Trial name
- NCT05203601
- Testing
- SIBP-03
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Shanghai Institute Of Biological Products
Breast Cancer
Study of Neoadjuvant Endocrine Therapy in HR Positive and HER2 Negative Premenopausal Breast Cancer Patients
A multicenter, prospective, open, randomized cohort, non controlled phase II clinical study to evaluate the effectiveness and safety of Darxil combined with Exemestane+goserelin neoadjuvant endocrine therapy in HR positive and…
- Trial name
- NCT06009627
- Testing
- dalpiciclib、Exemestane、Gosserine, Docetaxel for injection、Epirubicin hydrochloride for injection、Cyclophosphamide for injection
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer, Gastroesophageal Junction Cancer
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
The purpose of this study is to evaluate the efficacy of pembrolizumab (MK-3745) in the neoadjuvant (prior to surgery) or adjuvant (after surgery) treatment of previously untreated Chinese adults with gastric and gastroesophageal…
- Trial name
- NCT04882241
- Testing
- Pembrolizumab, Cisplatin, Capecitabine
- Where
- 20 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003519
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 134 sites in United States
- Volunteers
- 2,778 people
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Breast Cancer
Safety Study of a New Schedule of Capecitabine and Docetaxel to Treat Cancers
The combination of capecitabine and docetaxel is given to treat several different types of cancer. Capecitabine is usually given by mouth for 14 days, and docetaxel is given IV on the first day of capecitabine.
- Trial name
- NCT00169000
- Testing
- Capecitabine, Docetaxel
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer
Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)
This is a two-arm, randomized Phase II study of intermittent chemotherapy with and without GM-CSF. All patients will receive six 21-day cycles of docetaxel 75 mg/m2 on Day 2 of each cycle and 5 mg prednisone twice a day on Days…
- Trial name
- NCT00488982
- Testing
- Docetaxel, Docetaxel and GM-CSF
- Where
- 4 sites in United States
- Volunteers
- 125 people
- Sponsor
- University of California, San Francisco
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Temozolomide in Treating Patients With Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00401180
- Testing
- docetaxel, temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Cleveland Clinic
Breast Cancer
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Phase II randomized multicenter trial to compare Epirubicin and Cyclophosphamide plus Docetaxel and Trastuzumab with Epirubicin and Cyclophosphamide plus Docetaxel and Lapatinib for patients with positive HER2 and resectable or…
- Trial name
- NCT00841828
- Testing
- Epirubicin, Cyclophosphamide, Docetaxel
- Where
- 26 sites in Spain
- Volunteers
- 102 people
- Sponsor
- Spanish Breast Cancer Research Group
Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx
Phase 2 Sequential and Concurrent Chemoradiation for Advanced Nasopharyngeal Carcinoma (NPC)
This phase 2 trial is studying whether giving a combination of docetaxel, cisplatin, and fluorouracil chemotherapy followed by the combination of cisplatin with radiation therapy works in treating patients with advanced…
- Conditions
- Stage II Lymphoepithelioma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Nasopharynx
- Trial name
- NCT00896181
- Testing
- docetaxel, cisplatin, carboplatin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Stanford University
Metastatic Castration-resistant Prostate Cancer
Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
The VIABLE study sought to confirm the hypothesis that the combination of docetaxel with DCVAC/PCa followed by a maintenance therapy with DCVAC/PCa would improve overall survival in patients with metastatic castration-resistant…
- Trial name
- VIABLE (NCT02111577)
- Testing
- DCVAC/PCa
- Where
- 177 sites in United States, Austria and 20 more
- Volunteers
- 1,182 people
- Sponsor
- SOTIO a.s.
Solid Tumors
Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Participants With Solid Tumors
The purpose of this study is to establish the maximum tolerated dose (MTD) and assess the safety and tolerability of MLN4924 (pevonedistat) in combination with docetaxel, paclitaxel and carboplatin, and gemcitabine in…
- Trial name
- NCT01862328
- Testing
- MLN4924, Paclitaxel, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 64 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Prostatic Neoplasms
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate…
- Trial name
- NCT00401765
- Testing
- CNTO 328, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Centocor, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.